Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): Study protocol for a cluster randomised controlled trial

Katherine L. Fielding, Salome Charalambous, Christopher Hoffmann, Suzanne Johnson, Mpho Tlali, Susan E. Dorman, Anna Vassall, Gavin J. Churchyard, Alison D. Grant

Research output: Contribution to journalArticle

Abstract

Background: Early mortality for HIV-positive people starting antiretroviral therapy (ART) remains high in resource-limited settings, with tuberculosis the most important cause. Existing rapid diagnostic tests for tuberculosis lack sensitivity among HIV-positive people, and consequently, tuberculosis treatment is either delayed or started empirically (without bacteriological confirmation). We developed a management algorithm for ambulatory HIV-positive people, based on body mass index and point-of-care tests for haemoglobin and urine lipoarabinomannan (LAM), to identify those at high risk of tuberculosis and mortality. We designed a clinical trial to test whether implementation of this algorithm reduces six-month mortality among HIV-positive people with advanced immunosuppression. Methods/design: The TB Fast Track study is an open, pragmatic, cluster randomised superiority trial, with 24 primary health clinics randomised to implement the intervention or standard of care. Adults (aged ≥18 years) with a CD4 count of 150 cells/μL or less, who have not received any tuberculosis treatment in the last three months, or ART in the last six months, are eligible. In intervention clinics, the study algorithm is used to classify individuals as at high, medium or low probability of tuberculosis. Those classified as high probability start tuberculosis treatment immediately, followed by ART after two weeks. Medium-probability patients follow the South African guidelines for test-negative tuberculosis and are reviewed within a week, to be re-categorised as low or high probability. Low-probability patients start ART as soon as possible. The primary outcome is all-cause mortality at six months. Secondary outcomes include severe morbidity, time to ART start and cost-effectiveness. Discussion: This trial will test whether a primary care-friendly management algorithm will enable nurses to identify HIV-positive patients at the highest risk of tuberculosis, to facilitate prompt treatment and reduce early mortality. There remains an urgent need for better diagnostic tests for tuberculosis, especially for people with advanced HIV disease, which may render empirical treatment unnecessary.

Original languageEnglish (US)
Article number125
JournalTrials
Volume16
Issue number1
DOIs
StatePublished - Mar 28 2015

Fingerprint

Point-of-Care Systems
Tuberculosis
Randomized Controlled Trials
HIV
Mortality
Therapeutics
Routine Diagnostic Tests
Standard of Care
CD4 Lymphocyte Count
Immunosuppression
Cost-Benefit Analysis
Primary Health Care
Hemoglobins
Body Mass Index

Keywords

  • HIV infections
  • Mortality
  • Pragmatic clinic trials
  • Treatment
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study) : Study protocol for a cluster randomised controlled trial. / Fielding, Katherine L.; Charalambous, Salome; Hoffmann, Christopher; Johnson, Suzanne; Tlali, Mpho; Dorman, Susan E.; Vassall, Anna; Churchyard, Gavin J.; Grant, Alison D.

In: Trials, Vol. 16, No. 1, 125, 28.03.2015.

Research output: Contribution to journalArticle

Fielding, Katherine L. ; Charalambous, Salome ; Hoffmann, Christopher ; Johnson, Suzanne ; Tlali, Mpho ; Dorman, Susan E. ; Vassall, Anna ; Churchyard, Gavin J. ; Grant, Alison D. / Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study) : Study protocol for a cluster randomised controlled trial. In: Trials. 2015 ; Vol. 16, No. 1.
@article{2b978c96790f4fa4aab635e148a032ff,
title = "Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): Study protocol for a cluster randomised controlled trial",
abstract = "Background: Early mortality for HIV-positive people starting antiretroviral therapy (ART) remains high in resource-limited settings, with tuberculosis the most important cause. Existing rapid diagnostic tests for tuberculosis lack sensitivity among HIV-positive people, and consequently, tuberculosis treatment is either delayed or started empirically (without bacteriological confirmation). We developed a management algorithm for ambulatory HIV-positive people, based on body mass index and point-of-care tests for haemoglobin and urine lipoarabinomannan (LAM), to identify those at high risk of tuberculosis and mortality. We designed a clinical trial to test whether implementation of this algorithm reduces six-month mortality among HIV-positive people with advanced immunosuppression. Methods/design: The TB Fast Track study is an open, pragmatic, cluster randomised superiority trial, with 24 primary health clinics randomised to implement the intervention or standard of care. Adults (aged ≥18 years) with a CD4 count of 150 cells/μL or less, who have not received any tuberculosis treatment in the last three months, or ART in the last six months, are eligible. In intervention clinics, the study algorithm is used to classify individuals as at high, medium or low probability of tuberculosis. Those classified as high probability start tuberculosis treatment immediately, followed by ART after two weeks. Medium-probability patients follow the South African guidelines for test-negative tuberculosis and are reviewed within a week, to be re-categorised as low or high probability. Low-probability patients start ART as soon as possible. The primary outcome is all-cause mortality at six months. Secondary outcomes include severe morbidity, time to ART start and cost-effectiveness. Discussion: This trial will test whether a primary care-friendly management algorithm will enable nurses to identify HIV-positive patients at the highest risk of tuberculosis, to facilitate prompt treatment and reduce early mortality. There remains an urgent need for better diagnostic tests for tuberculosis, especially for people with advanced HIV disease, which may render empirical treatment unnecessary.",
keywords = "HIV infections, Mortality, Pragmatic clinic trials, Treatment, Tuberculosis",
author = "Fielding, {Katherine L.} and Salome Charalambous and Christopher Hoffmann and Suzanne Johnson and Mpho Tlali and Dorman, {Susan E.} and Anna Vassall and Churchyard, {Gavin J.} and Grant, {Alison D.}",
year = "2015",
month = "3",
day = "28",
doi = "10.1186/s13063-015-0650-0",
language = "English (US)",
volume = "16",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study)

T2 - Study protocol for a cluster randomised controlled trial

AU - Fielding, Katherine L.

AU - Charalambous, Salome

AU - Hoffmann, Christopher

AU - Johnson, Suzanne

AU - Tlali, Mpho

AU - Dorman, Susan E.

AU - Vassall, Anna

AU - Churchyard, Gavin J.

AU - Grant, Alison D.

PY - 2015/3/28

Y1 - 2015/3/28

N2 - Background: Early mortality for HIV-positive people starting antiretroviral therapy (ART) remains high in resource-limited settings, with tuberculosis the most important cause. Existing rapid diagnostic tests for tuberculosis lack sensitivity among HIV-positive people, and consequently, tuberculosis treatment is either delayed or started empirically (without bacteriological confirmation). We developed a management algorithm for ambulatory HIV-positive people, based on body mass index and point-of-care tests for haemoglobin and urine lipoarabinomannan (LAM), to identify those at high risk of tuberculosis and mortality. We designed a clinical trial to test whether implementation of this algorithm reduces six-month mortality among HIV-positive people with advanced immunosuppression. Methods/design: The TB Fast Track study is an open, pragmatic, cluster randomised superiority trial, with 24 primary health clinics randomised to implement the intervention or standard of care. Adults (aged ≥18 years) with a CD4 count of 150 cells/μL or less, who have not received any tuberculosis treatment in the last three months, or ART in the last six months, are eligible. In intervention clinics, the study algorithm is used to classify individuals as at high, medium or low probability of tuberculosis. Those classified as high probability start tuberculosis treatment immediately, followed by ART after two weeks. Medium-probability patients follow the South African guidelines for test-negative tuberculosis and are reviewed within a week, to be re-categorised as low or high probability. Low-probability patients start ART as soon as possible. The primary outcome is all-cause mortality at six months. Secondary outcomes include severe morbidity, time to ART start and cost-effectiveness. Discussion: This trial will test whether a primary care-friendly management algorithm will enable nurses to identify HIV-positive patients at the highest risk of tuberculosis, to facilitate prompt treatment and reduce early mortality. There remains an urgent need for better diagnostic tests for tuberculosis, especially for people with advanced HIV disease, which may render empirical treatment unnecessary.

AB - Background: Early mortality for HIV-positive people starting antiretroviral therapy (ART) remains high in resource-limited settings, with tuberculosis the most important cause. Existing rapid diagnostic tests for tuberculosis lack sensitivity among HIV-positive people, and consequently, tuberculosis treatment is either delayed or started empirically (without bacteriological confirmation). We developed a management algorithm for ambulatory HIV-positive people, based on body mass index and point-of-care tests for haemoglobin and urine lipoarabinomannan (LAM), to identify those at high risk of tuberculosis and mortality. We designed a clinical trial to test whether implementation of this algorithm reduces six-month mortality among HIV-positive people with advanced immunosuppression. Methods/design: The TB Fast Track study is an open, pragmatic, cluster randomised superiority trial, with 24 primary health clinics randomised to implement the intervention or standard of care. Adults (aged ≥18 years) with a CD4 count of 150 cells/μL or less, who have not received any tuberculosis treatment in the last three months, or ART in the last six months, are eligible. In intervention clinics, the study algorithm is used to classify individuals as at high, medium or low probability of tuberculosis. Those classified as high probability start tuberculosis treatment immediately, followed by ART after two weeks. Medium-probability patients follow the South African guidelines for test-negative tuberculosis and are reviewed within a week, to be re-categorised as low or high probability. Low-probability patients start ART as soon as possible. The primary outcome is all-cause mortality at six months. Secondary outcomes include severe morbidity, time to ART start and cost-effectiveness. Discussion: This trial will test whether a primary care-friendly management algorithm will enable nurses to identify HIV-positive patients at the highest risk of tuberculosis, to facilitate prompt treatment and reduce early mortality. There remains an urgent need for better diagnostic tests for tuberculosis, especially for people with advanced HIV disease, which may render empirical treatment unnecessary.

KW - HIV infections

KW - Mortality

KW - Pragmatic clinic trials

KW - Treatment

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84927155291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927155291&partnerID=8YFLogxK

U2 - 10.1186/s13063-015-0650-0

DO - 10.1186/s13063-015-0650-0

M3 - Article

C2 - 25872501

AN - SCOPUS:84927155291

VL - 16

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 125

ER -